AstraZeneca Bets Cancer Picks Up Diabetes Slack in New PlanBy
New long-term plan reflects confidence in Lynparza, AZD9291
Diabetes drugs in U.S. not performing as well as expected
AstraZeneca Plc projected a slowdown in U.S. sales of diabetes treatments, echoing comments by competitors and putting the onus on its cancer drugs to help meet its long-term sales target.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.